AMICUS THERAPEUTICS, INC. — Director's Dealing 2020

Jul 9, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2020-07-07

Reporting Person: Barth Jay (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-07-07	Common Stock	M	51531	$8.61	Acquired	214735	Direct
2020-07-07	Common Stock	M	64601	$9.03	Acquired	279336	Direct
2020-07-07	Common Stock	M	12804	$10.04	Acquired	292140	Direct
2020-07-07	Common Stock	M	50052	$12.28	Acquired	342192	Direct
2020-07-07	Common Stock	S	178988	$15.9002	Disposed	163204	Direct
2020-07-08	Common Stock	M	16910	$8.61	Acquired	180114	Direct
2020-07-08	Common Stock	M	16549	$9.03	Acquired	196663	Direct
2020-07-08	Common Stock	M	8599	$10.04	Acquired	205262	Direct
2020-07-08	Common Stock	M	22052	$12.28	Acquired	227314	Direct
2020-07-08	Common Stock	S	64110	$15.9191	Disposed	163204	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-07	Stock Options (right to buy)	$8.61	M	51531	Disposed	2025-01-02	Common Stock (51531)	Direct
2020-07-07	Stock Options (right to buy)	$9.03	M	64601	Disposed	2026-01-04	Common Stock (64601)	Direct
2020-07-07	Stock Options (right to buy)	$10.04	M	12804	Disposed	2029-01-02	Common Stock (12804)	Direct
2020-07-07	Stock Options (right to buy)	$12.28	M	50052	Disposed	2025-06-01	Common Stock (50052)	Direct
2020-07-08	Stock Options (right to buy)	$8.61	M	16910	Disposed	2025-01-02	Common Stock (16910)	Direct
2020-07-08	Stock Options (right to buy)	$9.03	M	16549	Disposed	2026-01-04	Common Stock (16549)	Direct
2020-07-08	Stock Options (right to buy)	$10.04	M	8599	Disposed	2029-01-02	Common Stock (8599)	Direct
2020-07-08	Stock Options (right to buy)	$12.28	M	22052	Disposed	2025-06-01	Common Stock (22052)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	20	Indirect

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.90 to $15.91. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.90 to $16.12 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: All of the options were fully vested and exercisable as of the transaction date.

F5: As of July 7, 2020, 30,987 options were fully vested and exercisable and 51,657 remained unvested from this grant.

F6: As of July 8, 2020, 18,183 options were fully vested and exercisable and 51,657 remained unvested from this grant.